secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2026-09-18T21:10:19+00:00
Accession:  0001493152-26-043389
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack director Paul V. Goode resigns citing potential conflict of interest
-------------------------------------------------------------------------------

- Paul V. Goode resigned from Glucotrack board effective Sept. 14, 2026.
- Resignation cites potential conflict between company and subsidiary under Lokahi Therapeutics merger agreement.
- Company provided resignation notice as Exhibit 17.1; Goode may file disagreement letter.
- CEO Erik Emerson signed the 8-K; no replacement director named.
- Conflict relates to implementing duties, rights, and obligations of entities in the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226043389/0001493152-26-043389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226043389/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-043389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer